How men gain - and lose - metabolic risk
Metabolic risk in men tends to accumulate slowly: a few extra kilos around the waist, sleep that is steadily worse than it used to be, alcohol that adds up across a busy week, and a decade of stress without much recovery. The biology that follows - rising insulin, falling testosterone, more visceral fat, worse sleep, higher blood pressure - reinforces itself until something forces a stop.
The good news is that the same biology runs in reverse. Modest weight loss (5–10% of body weight) is consistently associated with better insulin sensitivity, lower triglycerides, higher HDL, lower blood pressure, and meaningful improvements in testosterone and energy. Sustained weight loss compounds these gains and reduces long-term cardiovascular and metabolic disease risk.
Where weight-loss medications fit
For men with elevated BMI or with metabolic risk markers that haven't responded to lifestyle change, GLP-1 receptor agonists (such as semaglutide and liraglutide) and dual-receptor agonists are now part of mainstream guideline-based care. Trials show double-digit weight loss alongside improvements in blood-glucose control, blood pressure, and cardiovascular outcomes in eligible patients.
These medications are not a shortcut around lifestyle - they are a tool that works best alongside it, under medical review, with attention to nutrition, muscle mass and side effects. Eligibility, dosing and monitoring should always be assessed by a clinician.
The testosterone connection
Visceral fat increases the conversion of testosterone to oestradiol via aromatase, and obesity is one of the most common reversible causes of low testosterone in men. In some men, weight loss alone restores testosterone levels - in others, addressing both metabolic and hormonal health together gives the best result. The right answer depends on your blood work, history and goals, which is why a clinician's review matters.
Monitoring matters
Whether you take a lifestyle-only route or include medication, ongoing review keeps you safe and on track. Follow-up typically covers weight and waist, blood pressure, lipids, HbA1c and liver enzymes, plus symptoms, sleep, energy and side-effects. Plans are adjusted based on what the data and how you feel are telling us.
Sources
- Endocrine Society: Pharmacological Management of Obesity Clinical Practice Guideline
- NICE CG189: Obesity - identification, assessment and management
- ESC 2021 Guidelines on Cardiovascular Disease Prevention in Clinical Practice
- Effect of weight loss on testosterone in obese and overweight men (systematic review)